Intra-Cellular Therapies Inc. (ITCI) Social Stream
INTRA-CELLULAR THERAPIES INC (ITCI) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ITCI.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 7 | $70 | $45 | $53 | $70.75 | -25.09% |
| 2021-12-06 | 7 | $70 | $45 | $53.428 | $70.75 | -24.48% |
| 2021-12-20 | 7 | $85 | $46 | $56.666 | $70.75 | -19.91% |
| 2021-12-21 | 6 | $85 | $46 | $59.285 | $70.75 | -16.2% |
| 2022-01-06 | 7 | $85 | $46 | $59.428 | $70.75 | -16% |
| 2022-01-23 | 7 | $85 | $46 | $60 | $70.75 | -15.19% |
| 2022-01-28 | 7 | $85 | $46 | $60.142 | $70.75 | -14.99% |
| 2022-03-02 | 7 | $85 | $49 | $60.571 | $70.75 | -14.39% |
| 2022-03-08 | 7 | $90 | $55 | $65.142 | $70.75 | -7.93% |
| 2022-04-13 | 7 | $90 | $55 | $65.857 | $70.75 | -6.92% |
| 2022-04-21 | 8 | $90 | $55 | $66.571 | $70.75 | -5.91% |
| 2022-05-11 | 8 | $90 | $55 | $66.75 | $70.75 | -5.65% |
| 2022-05-16 | 10 | $90 | $55 | $66.555 | $70.75 | -5.93% |
| 2022-06-14 | 10 | $90 | $55 | $67.4 | $70.75 | -4.73% |
| 2022-08-09 | 11 | $90 | $55 | $67.545 | $70.75 | -4.53% |
| 2022-08-15 | 11 | $90 | $57 | $69.727 | $70.75 | -1.45% |
| 2022-10-13 | 11 | $90 | $49 | $68.363 | $70.75 | -3.37% |
| 2022-11-03 | 11 | $90 | $49 | $67.636 | $70.75 | -4.4% |
| 2022-11-04 | 11 | $93 | $49 | $70.166 | $70.75 | -0.83% |
| 2023-02-08 | 11 | $93 | $49 | $70.083 | $70.75 | -0.94% |
| 2023-02-13 | 11 | $93 | $49 | $70.5 | $70.75 | -0.35% |
| 2023-03-01 | 11 | $93 | $49 | $70.916 | $70.75 | 0.23% |
| 2023-03-02 | 11 | $93 | $49 | $70.75 | $70.75 | 0% |
| 2023-03-28 | 11 | $93 | $49 | $70.666 | $70.75 | -0.12% |
| 2023-03-29 | 12 | $93 | $49 | $70.666 | $70.75 | -0.12% |
| 2023-04-05 | 12 | $98 | $49 | $71.666 | $70.75 | 1.29% |
| 2023-04-17 | 12 | $98 | $49 | $72 | $70.75 | 1.77% |
| 2023-05-04 | 13 | $98 | $49 | $73.384 | $70.75 | 3.72% |
| 2023-05-08 | 13 | $98 | $49 | $74.153 | $70.75 | 4.81% |
| 2023-06-06 | 13 | $98 | $49 | $74.461 | $70.75 | 5.25% |
| 2023-06-30 | 11 | $98 | $49 | $75.916 | $70.75 | 7.3% |
| 2023-08-03 | 11 | $98 | $49 | $76.5 | $70.75 | 8.13% |
| 2023-08-04 | 11 | $98 | $59 | $79.909 | $70.75 | 12.95% |
| 2023-10-12 | 10 | $98 | $59 | $79.909 | $70.75 | 12.95% |
| 2023-11-02 | 11 | $98 | $59 | $78.666 | $70.75 | 11.19% |
| 2023-11-03 | 11 | $101 | $59 | $79.083 | $70.75 | 11.78% |
| 2023-11-04 | 13 | $101 | $59 | $77.538 | $70.75 | 9.59% |
| 2023-12-13 | 13 | $101 | $59 | $77.357 | $70.75 | 9.34% |
| 2023-12-19 | 14 | $101 | $59 | $77.785 | $70.75 | 9.94% |
The Trend in the Analyst Price Target
Over the past 17 months, ITCI's average price target has gone up $10.17.
Over the past 47 weeks, ITCI's average upside potential has been 33.5%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-06-06 | 13 | 98 | 49 | 74.416 | 65.41 | 13.77% |
| 2023-06-30 | 11 | 98 | 49 | 75.916 | 63.32 | 19.89% |
| 2023-07-06 | 11 | 98 | 49 | 76.500 | 64.10 | 19.34% |
| 2023-08-04 | 10 | 98 | 49 | 77.333 | 58.52 | 32.15% |
| 2023-11-04 | 11 | 101 | 59 | 78.833 | 54.99 | 43.36% |
ITCI Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.46 | 9 | 2 | 2 | 0 | 0 | 13 |
The Trend in the Broker Recommendations
Over the past 22 months, ITCI's average broker recommendation rating worsened by 0.17.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ITCI has a greater upside potential (average analyst target price relative to current price) than 811.02% of Pharmaceutical Products stocks.
- In terms of how INTRA-CELLULAR THERAPIES INC fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 4398.47% of that group.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, INTRA-CELLULAR THERAPIES INC's number of analysts covering the stock is greater than 3993.76% of them.
- INTRA-CELLULAR THERAPIES INC's variance in analysts' estimates is lower than -3706.91% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, IRWD, PCRX, and EBS are the three stocks most similar to INTRA-CELLULAR THERAPIES INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Make investment decisions regarding ITCI using the data that counts. Try POWR Ratings for free.